Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Dyne Therapeutics (Nasdaq: DYN), a clinical-stage neuromuscular disease company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. John Cox, the company's president and chief executive officer, will deliver a presentation on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET).

The presentation will be accessible through a live webcast on the Investors & Media section of Dyne's website. Interested parties can view the replay for 30 days after the presentation through the company's investor relations portal at investors.dyne-tx.com.

Dyne Therapeutics focuses on developing innovative life-transforming therapeutics for individuals affected by genetically driven diseases.

WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 43^rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2025 at 10:30 a.m. PT (1:30 p.m. ET).

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 30 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is focused on discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook. 

Contacts:

Investors
Mike Hencke
Kendall Investor Relations
ir@dyne-tx.com

Media
Stacy Nartker
Dyne Therapeutics
snartker@dyne-tx.com
781-317-1938

FAQ

When is Dyne Therapeutics (DYN) presenting at the 2025 J.P. Morgan Healthcare Conference?

Dyne Therapeutics is scheduled to present on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET) at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.

How can investors watch Dyne Therapeutics' (DYN) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation through a live webcast available in the Investors & Media section of Dyne's website at investors.dyne-tx.com. A replay will be accessible for 30 days following the presentation.

What is the focus area of Dyne Therapeutics (DYN)?

Dyne Therapeutics is a clinical-stage neuromuscular disease company focused on developing innovative life-transforming therapeutics for people living with genetically driven diseases.

Who will represent Dyne Therapeutics (DYN) at the 2025 J.P. Morgan Healthcare Conference?

John Cox, president and chief executive officer of Dyne Therapeutics, will represent the company at the conference.